G
24.94
as on 26 Jun 2025 at 15:19
BSE
Market Cap
₹26 Cr
PE Ratio
125.10
ROCE
-5.09%
Today Global Longlife Hospital & Research opened at 23.70 while its previous close was at 23.76. In todays trading session GLHRL reached a high of 24.94 and low of 23.70. The average traded price for today is 24.11. The 50 DMA stands at and 200 DMA is at . Looking at intraday trend, the stock is in Uptrend.
Get 10+ Layouts, 100+ Indicators, Custom Timeframes & All Drawing Tools for FREE.
High
24.94
Low
23.70
Open at
23.70
Prev Close
23.76
Volumes
3,000
Avg Price
24.11
Lower Circuit
23.70
Upper Circuit
26.18
Quantity
1,000
Time
15:19:52
3 M High
33.02
3 M Low
18.30
1 Yr High
46.44
1 Yr Low
18.30
3 Yr High
93.50
3 Yr Low
18.30
5 Yr High
141.10
5 Yr Low
18.30
HDFC Bank: Shares Hit Record High, Surpassing ₹2,000 Mark
HDFC Bank shares reached a record high of ₹2,017.7, crossing the ₹2,000 mark. The stock has gained 14% in 2025, making it the best year since 2019. Analysts maintain a bullish outlook with potential targets of ₹2,186 and ₹2,220. The bank's non-bank lending unit, HDB Financial Services, has a fully subscribed IPO.
Lupin: Launches Bowel Disorder Drug in US Market
Lupin Ltd has launched Prucalopride tablets in the US after USFDA approval. The drug, used for chronic idiopathic constipation, has an estimated annual US market size of $184 million. It will be manufactured at Lupin's Goa facility.
FSN E-Commerce Ventures Ltd: Nykaa Launches Quick Commerce, Sets Fashion Business Targets
Nykaa launched 'Nykaa Now', a quick commerce platform for beauty products in 7 cities. The company expects its fashion business to break even in FY26 with mid-single digit margins by FY28. Nykaa aims to grow 3-4 times in the next 5 years and targets 10% steady state EBITDA margins for fashion. Own brands reported 2,100 crore GMV across 12 brands, with organic portfolio expected to grow at 30% CAGR to 6,000 crore GMV by FY30.
Prozo: Indian Cricketer Rohit Sharma Invests in Supply Chain Firm
Indian cricketer Rohit Sharma has made a strategic investment in supply chain firm Prozo. The company has raised $20 million to date from investors including Sixth Sense Ventures and Jafco Asia. Prozo operates 42 tech-enabled warehouses covering 2.2 million square feet and is operating at a revenue run-rate of Rs 250 crore.
Mahindra & Mahindra: EV Production Capacity Surges to 8,000 Units Monthly
Mahindra & Mahindra has increased its electric vehicle production capacity to 8,000 units per month. The company received 30,179 EV bookings on the first day, valued at Rs 8,472 crore. Mahindra plans to launch seven Born Electric Vehicles by 2030 and is developing a new EV platform with a capacity of 1.2 lakh units at its Chakan facility.
Titan Company: Shares Rally 25% from 52-Week Low, Analysts See Further 9% Upside
Titan Company shares have risen 25% from their 52-week low, breaking out of resistance. Axis Securities predicts further upside to Rs 3,885-4,000 levels. The stock closed at Rs 3,622, showing a strong bullish trend with increased trading volumes. Technical indicators suggest continued momentum.
Transformers And Rectifiers India: Ambitious $1 Billion Revenue Target Set for FY28
Transformers and Rectifiers India Ltd. aims for $1 billion revenue by FY28, with FY26 target at Rs 3,500 crore. The company plans full backward integration by mid-next fiscal year, expecting to improve margins by 2-2.5%. Current order book stands at Rs 5,400 crore, with Rs 8,000 crore expected by fiscal year-end. Investing Rs 500 crore in backward integration and expanding extra-high voltage transformer capacity.
Fiem Industries: Auto Component Maker's Stock Soars Over 900% in Five Years
Fiem Industries Ltd., an auto components manufacturer, has seen its stock price surge by over 900% in the last five years. The stock has a year-to-date return of 26.46% and a 12-month return of 392.15%. Analysts maintain a positive outlook, with four out of seven recommending 'buy' and three suggesting 'hold'. The target price is set at Rs 1,999, indicating a potential 6.7% upside.
Close Price
Volume
GLHRL share price in last 10 trading sessions
Market Cap (₹ Cr.)
26
PE Ratio
125.10
PB Ratio
0.93
Dividend Yield
-
ROE
-8.44%
ROCE
-5.09%
Book Value (₹)
25.51
Face Value (₹)
10.00
Held By | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
---|---|---|---|---|---|
Promoters | 54.29% | 54.29% | 54.29% | 54.29% | 54.29% |
Domestic Institutional Investors (DII) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Foreign Institutional Investors (FII) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Public Investors | 37.13% | 34.62% | 31.90% | 31.79% | 33.71% |
Government | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Promoters
Domestic Institutional Investors (DII)
Foreign Institutional Investors (FII)
Public Investors
Government
1 Week
1 Month
3 Months
6 Months
9 Months
1 Year
2 Years
3 Years
4 Years
5 Years
1 Week
1 Month
3 Months
6 Months
9 Months
Create Wealth in Longterm with Weekly and Monthly SIP in Stocks.
Period | Simple | Signal |
---|---|---|
5-SMA | 26.68 | Bearish |
10-SMA | 28.39 | Bearish |
20-SMA | 28.10 | Bearish |
50-SMA | 31.35 | Bearish |
100-SMA | 35.89 | Bearish |
200-SMA | 39.88 | Bearish |
Indicator | Value | Action |
---|---|---|
RSI(14) | 39.26 | Neutral |
ATR(14) | 1.93 | Less Volatile |
STOCH(9,6) | 30.03 | Neutral |
STOCH RSI(14) | 12.56 | Oversold |
MACD(12,26) | -0.14 | Bearish |
ADX(14) | 18.28 | Weak Trend |
Summary of Technical Indicators for GLHRL
In Crores
In Crores
In Crores
In Crores
Get In-depth View of GLHRL Quaterly Results, Balance Sheet, Cashflows & Corporate Action.
All values are in Crores
Revenue
Profit
Loss
S
Sun Pharmaceutical
1,669.80
D
Divis Laboratories
6,616.00
C
Cipla
1,513.80
D
Dr Reddys Laboratories
1,321.50
Z
Zydus Life Science
981.95
M
Mankind Pharma
2,303.50
L
Lupin
1,928.70
A
Abbott
33,055.00
A
Aurobindo Pharma
1,123.20
A
Alkem Laboratories
4,841.00
G
GlaxoSmithKline Pharmaceuticals
3,301.90
G
Glenmark Pharmaceuticals
1,732.00
B
Biocon
350.50
C
Cohance Lifesciences
1,002.00
S
Sun Pharmaceutical
1,669.80
D
Divis Laboratories
6,616.00
C
Cipla
1,513.80
D
Dr Reddys Laboratories
1,321.50
Z
Zydus Life Science
981.95
M
Mankind Pharma
2,303.50
L
Lupin
1,928.70
A
Abbott
33,055.00
A
Aurobindo Pharma
1,123.20
A
Alkem Laboratories
4,841.00
G
GlaxoSmithKline Pharmaceuticals
3,301.90
G
Glenmark Pharmaceuticals
1,732.00
B
Biocon
350.50
C
Cohance Lifesciences
1,002.00
S
Sun Pharmaceutical
1,669.80
D
Divis Laboratories
6,616.00
C
Cipla
1,513.80
D
Dr Reddys Laboratories
1,321.50
Z
Zydus Life Science
981.95
M
Mankind Pharma
2,303.50
L
Lupin
1,928.70
A
Abbott
33,055.00
A
Aurobindo Pharma
1,123.20
A
Alkem Laboratories
4,841.00
G
GlaxoSmithKline Pharmaceuticals
3,301.90
G
Glenmark Pharmaceuticals
1,732.00
B
Biocon
350.50
C
Cohance Lifesciences
1,002.00
S
Sun Pharmaceutical
1,669.80
D
Divis Laboratories
6,616.00
C
Cipla
1,513.80
D
Dr Reddys Laboratories
1,321.50
Z
Zydus Life Science
981.95
M
Mankind Pharma
2,303.50
L
Lupin
1,928.70
A
Abbott
33,055.00
A
Aurobindo Pharma
1,123.20
A
Alkem Laboratories
4,841.00
G
GlaxoSmithKline Pharmaceuticals
3,301.90
G
Glenmark Pharmaceuticals
1,732.00
B
Biocon
350.50
C
Cohance Lifesciences
1,002.00
At this moment, No news for this stock
Pay Zero Brokerage on Delivery
Open FREE Demat Account
+91
Or Scan the QR Code to download the Dhan App
Explore | Sitemap
*All securities mentioned on this website are exemplary and not recommendatory.
*Current prices on the website are delayed by 15 mins, login to check live prices.
We are bullish on India, we are bullish on India's prospects to be one of the largest economies in the world. We believe that the stock market provides a unique opportunity for all of India's traders and investors to participate in the growth story of the country.
Yet, most investing & trading platforms in India have remained more or less the same over the past decade. Times have changed and retail traders and investors have become smarter about managing their trades and money. Modern traders & investors require an online trading platform that helps them keep up with the technological advancements of our time.
That's why we're building Dhan - to help you trade, to help you invest, and to help you participate in India's growth stock via the stock market with awesome features and an incredible experience.
©2021-2025 Moneylicious Securities Private Limited. All rights reserved. CIN: U74999MH2012PTC433549 Moneylicious Securities is part of Raise Financial Services.
In case of grievances for any of the services rendered by Moneylicious Securities Private Limited, please write to grievance@dhan.co (for NSE, BSE and MCX) or grievancedp@dhan.co (for Depository Participant). Please ensure that you carefully read the Risk Disclosure Document as prescribed by SEBI, our Terms of Use and Privacy Policy. Compliance Officer: Mr. Manish Garg and Mobile: 8655740961 Email: complianceofficer@dhan.co To lodge your complaints using SEBI SCORES, click here.
Disclaimer: All communications with the client via chat, phone, or email are for support purposes only. Any commitments or statements made by the agent (human or virtual) shall not be binding on the company.
DHAN is a brand owned by Moneylicious Securities Private Limited. All DHAN clients are registered under Moneylicious Securities Private Limited. Clients are advised to refer to our company as Moneylicious Securities Private Limited when communicating with regulatory authorities.
Procedure to file a complaint on SEBI SCORES: Register on SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID. Benefits: Effective Communication, Speedy redressal of the grievances
Disclaimer: Investment in the securities market are subject to market risks, read all the related documents carefully before investing. Brokerage will not exceed the SEBI prescribed limit
Attention investors:
Note: As a policy we do not give stock tips or recommendations and have not authorized anyone to give this on behalf of us. If you know anyone claiming to be a part of Dhan / Moneylicious / Raise or our associate companies or partners and offering such services, please report us on help@dhan.co. Important Information for Investors: To prevent unauthorized transactions in your trading / demat account, do not share your account details, credentials or any personal details with anyone. Keep your mobile number updated with your Stock Broker, Depository Participant and ensure that the same is registered with Stock Exchanges, Depository and KRAs. You will receive alerts and information on your registered mobile number / email for debit and other important transactions in your demat account directly from CDSL / Exchange on the same day. KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (Stock Broker, DP, Mutual Fund, etc.), you need not undergo the same process again when you approach another intermediary. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account. This is issued in the interest of investors.
Moneylicious Securities Private Limited also known as Dhan is only an order collection platform that collects orders on behalf of clients and places them on BSE StarMF for execution. Client expressly agrees that Dhan is not liable or responsible and does not represent or warrant any damages regarding non- execution of orders or any incorrect execution of orders with regard to the funds chosen by the client or due to, but not being limited to, any link/system failure, delay in transfer of the funds on account of any unforeseen circumstances/issues in the banking system/payment aggregators or any other problems that may result in a delay in crediting the funds into the BSE Star MF's bank account.
Mutual fund investments are subject to market risks, read all scheme related documents carefully before investing. Dhan is not a distributor or agent of any mutual fund. Mutual Funds are not exchange-traded products. Any related disputes will not have access to the Exchange-investor redressal forum or arbitration mechanism. For other disclaimers please refer https://dhan.co/advertisement-disclaimer/
Download client registration documents (Rights & Obligations, Risk Disclosure Document, Do's & Don'ts) in vernacular language: BSE | NSE | MCX
Kindly, read the Advisory Guidelines of BSE | NSE | MCX for investors as prescribed by the exchange with reference to their circular dated 27th August, 2021 regarding investor awareness and safeguarding client's assets